Gene editing news - the latest biotech news from Labiotech.eu

Genetic engineering giants: is China poised to lead the way?

Willow Shah-Neville — Wed, 19 Jul 2023 15:57:04 +0000

For many people, when they hear China and genetic engineering in the same sentence, it is often synonymous with scandal, and gene-edited babies may spring to mind. And, although it is true that nearly five years ago, researcher He Jiankui infamously claimed he had created the first ever gene-edited babies, before going to prison for […]

The post Genetic engineering giants: is China poised to lead the way? appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

New platform cuts time engineering and selecting genome editors

Jim Cornall — Wed, 28 Jun 2023 13:41:44 +0000

A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has developed a new way to break through the current limited throughput in optimizing precise genome editors at scale, engineer hundreds of base editor variants in parallel instead of current one-by-one testing, and informing users of the most suitable ones […]

The post New platform cuts time engineering and selecting genome editors appeared first on Labiotech.eu.

HuidaGene Therapeutics creates world’s first ‘G to Y’ DNA base-editor

Jim Cornall — Tue, 23 May 2023 09:00:00 +0000

HuidaGene Therapeutics, a clinical-stage genome-editing company, says the National Science Review has published data from its study of the world’s first DNA base editor converting guanine to cytosine/thymine (pyrimidine), or G-to-Y. The company has filed an international patent application for the glycosylase-based guanine base editor (gGBE) and owns the exclusive global rights to the underlying […]

The post HuidaGene Therapeutics creates world’s first ‘G to Y’ DNA base-editor appeared first on Labiotech.eu.

Five advancements in lupus research over the past year

Roohi Mariam Peter — Thu, 04 May 2023 11:56:51 +0000

A condition that affects around five million people worldwide, lupus has no proven cure. But various treatments for the disease have been around for more than a century, and lupus research has grown over the years. The first kind of therapy for the autoimmune disease – which occurs due to an overactive immune system that […]

The post Five advancements in lupus research over the past year appeared first on Labiotech.eu.

Eterna acquires allogeneic immuno-oncology platform from Exacis

Jim Cornall — Wed, 03 May 2023 14:26:47 +0000

Eterna Therapeutics Inc. has announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics. The acquisition complements Eterna Therapeutics’ core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna Therapeutics with an exclusive global license to produce an unlimited number of mRNA-engineered […]

The post Eterna acquires allogeneic immuno-oncology platform from Exacis appeared first on Labiotech.eu.

Beyond Biotech podcast 38: Hello Tomorrow Global Summit

Jim Cornall — Fri, 17 Mar 2023 11:47:18 +0000

The Hello Tomorrow Global Summit took place in Paris last week (March 8-10), and we feature interviews with four of the participants. Our guests this week are: FreezeM CEO and co-founder, Dr. Yuval Gilad; Allogenica CEO and co-founder Inna Menkova; George Frodsham, founder and CEO of MediSieve; and Poulami Chaudhuri, co-founder, and CEO of Helex […]

The post Beyond Biotech podcast 38: Hello Tomorrow Global Summit appeared first on Labiotech.eu.

Can CRISPR bring back extinct animals?

Willow Shah-Neville — Fri, 10 Mar 2023 15:12:47 +0000

The concept of de-extinction has been around for many years. Once considered a fanciful idea, recent advancements in technology – notably CRISPR – have made bringing back extinct animals such as mammoths an extremely feasible proposition that investors are willing to put their money into, with an aim of reversing and preventing biodiversity loss. The […]

The post Can CRISPR bring back extinct animals? appeared first on Labiotech.eu.

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Jim Cornall — Thu, 23 Feb 2023 10:26:34 +0000

Moderna, Inc., a biotechnology company working on messenger RNA (mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., an ElevateBio company focused on gene editing technologies and therapeutics, have announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary […]

The post Moderna and Life Edit Therapeutics look to speed up gene editing therapies appeared first on Labiotech.eu.

AI boosts genome editing

Jim Cornall — Fri, 03 Feb 2023 08:13:47 +0000

Researchers at the University of Zurich have developed a new tool that uses artificial intelligence to predict the efficacy of various genome-editing repair options. Unintentional errors in the correction of DNA mutations of genetic diseases can thus be reduced. Genome editing technologies offer great opportunities for treating genetic diseases. Methods such as the widely used […]

The post AI boosts genome editing appeared first on Labiotech.eu.

Milestone for gene-edited therapy for sickle cell disease

Jim Cornall — Thu, 26 Jan 2023 08:27:46 +0000

Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics have announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application of exa-cel for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The submission is supported by two global phase 3 studies investigating exa-cel as a potential one-time therapy for people with […]

The post Milestone for gene-edited therapy for sickle cell disease appeared first on Labiotech.eu.

PACT Pharma reports data from CRISPR cancer study

Jim Cornall — Fri, 11 Nov 2022 11:46:19 +0000

PACT Pharma, Inc. has reported data from the first clinical study using CRISPR gene editing technology to substitute a gene in patients’ immune cells to treat cancer. Results from the study, which was conducted with collaborators at nine academic centers using PACT Pharma’s platforms, demonstrated early proof-of-concept that a patient’s immune system can be reprogrammed […]

The post PACT Pharma reports data from CRISPR cancer study appeared first on Labiotech.eu.

What’s on the horizon for gene editing-based therapies?

Jonathan Smith — Thu, 03 Nov 2022 17:35:23 +0000

Gene editing has come far in the past decade. However, the field is still finding its feet regarding challenges such as drug delivery, regulation and competition with first-generation gene therapies. Gene editing is a sizzling hot topic in the biotech industry, powered by advances in genetic tools such as CRISPR, TALENs and zinc-finger nucleases. Gene […]

The post What’s on the horizon for gene editing-based therapies? appeared first on Labiotech.eu.

Opportunities and challenges for cell and gene therapy investments

Jonathan Smith — Thu, 20 Oct 2022 15:39:31 +0000

Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could be an opportunity for the strongest companies and investors to shine. After several years of record-breaking investments, funding is hard to come by in the gene and cell therapy space. Part of this trend relates […]

The post Opportunities and challenges for cell and gene therapy investments appeared first on Labiotech.eu.

CRISPR gene editing: a key tool for counteracting climate change

Jonathan Smith — Mon, 17 Oct 2022 10:18:14 +0000

Monika Paulė, CEO and co-founder of the Lithuanian CRISPR developer Caszyme, explains how gene editing technology could fight climate change by boosting agriculture and biodiversity. The invention of CRISPR-Cas gene editing technology in the last decade sparked a revolution in biology, providing researchers a way to make selective and precise changes to an organism’s genetic […]

The post CRISPR gene editing: a key tool for counteracting climate change appeared first on Labiotech.eu.

The challenges of translating CRISPR to the clinic

Jim Cornall — Mon, 17 Oct 2022 07:17:00 +0000

CRISPR-Cas9 is revolutionizing all facets of drug discovery, allowing for both a deeper understanding of disease processes, and for the development of ground-breaking genetic medicines. As these new classes of cell and gene therapies translate to the clinical setting, some key bottlenecks remain to be solved before the technology will realize its full societal impact. […]

The post The challenges of translating CRISPR to the clinic appeared first on Labiotech.eu.

Removing binding sites for an oncogene can slow cancer cell growth, researchers say

Liza Laws — Thu, 29 Sep 2022 15:13:48 +0000

Cancer cell growth could be slowed down by removing binding sites for an oncogene, researchers from the University of Helsinki have discovered. They have found a mechanism by which an oncogene commonly activated in cancer patients affects the growth rate of cells. In the future, the findings can help in developing new treatments that could […]

The post Removing binding sites for an oncogene can slow cancer cell growth, researchers say appeared first on Labiotech.eu.

Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies

Liza Laws — Wed, 28 Sep 2022 17:57:29 +0000

Scribe Therapeutics has entered into an agreement with Sanofi which will allow Sanofi use of its CRISPR genome editing technologies. Scribe Therapeutics’ custom genome editing and delivery tools called CasX-Editors (XE) based on foundations such as the CasX enzyme will enable genetic modification of natural killer (NK) cell therapies for cancer and will support Sanofi’s […]

The post Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies appeared first on Labiotech.eu.

Lesaffre acquires genome editing company Recombia Biosciences

Jim Cornall — Wed, 07 Sep 2022 16:12:51 +0000

Lesaffre has acquired Recombia Biosciences, a biotech company based in the San Francisco Bay Area founded in 2019 based on technology licensed from Stanford University. This acquisition is the culmination of a strategic partnership initiated in 2020 to leverage Recombia Biosciences’ genome-editing technologies and accelerate the development of yeasts for sustainable production of fermented ingredients. […]

The post Lesaffre acquires genome editing company Recombia Biosciences appeared first on Labiotech.eu.

Gene therapies for lung cancer identified by international team of scientists

Liza Laws — Wed, 24 Aug 2022 16:29:32 +0000

Gene therapies for lung cancer can be found by CRISPR genome editing technology, an international team of scientists have discovered. CRISPR genome-editing is a powerful tool that gives scientists a cheap and easy way to find and alter a specific piece of DNA within a cell – the ‘cut and paste’ of the biological world. […]

The post Gene therapies for lung cancer identified by international team of scientists appeared first on Labiotech.eu.

Optimizing bioproduction using transient expression systems

Sudha Sundaram — Tue, 16 Aug 2022 08:00:52 +0000

During drug development, biologics often fail to transition from the preclinical to the clinical stage, resulting in huge losses in time and money. We explore how choosing the right expression system and optimizing a method known as transient protein expression may offer a potential solution. Bioproduction is the use of living systems to produce complex […]

The post Optimizing bioproduction using transient expression systems appeared first on Labiotech.eu.